基于横截面积的0.375%罗哌卡因在L形挡板干预下锁骨上臂丛神经阻滞的ED50研究
2025-08-03张亮光张龙庞如发邱雯赵劲松戚建武


[摘要] 目的 探讨0.375%罗哌卡因在L形挡板干预下锁骨上臂丛神经阻滞(supraclavicular brachial plexus block,SCBPB)基于横截面积(cross sectional area,CSA)用药的半数有效量(median effective dose,ED50)。方法 选取2023年9月至2024年5月于宁波市第六医院择期行上肢手术的患者,随机分为L形挡板加压组(L组)和不加压组(C组)。通过超声测量锁骨上臂丛神经CSA,并根据CSA注射0.375%罗哌卡因。采用Dixon序贯法测定,初始剂量为0.4ml/mm2,剂量梯度为0.04ml/mm2。如果30min内阻滞有效,则下一例患者接受低一级剂量;若无效,则升一级剂量。持续该过程至出现7个上下交叉拐点(阻滞无效转为有效)。采用Probit法计算ED50及其95%CI,并记录膈肌麻痹、神经损伤及呼吸困难等不良反应。结果 C组患者0.375%罗哌卡因ED50为0.254ml/mm2(95%CI:0.228~0.278);L组患者0.375%罗哌卡因ED50为0.239ml/mm2(95%CI:0.215~0.262),组间差异无统计学意义(Pgt;0.05)。L组患者膈肌麻痹发生率显著低于C组(14.29% vs. 41.67%,Plt;0.05),且未发现明显的神经损伤、呼吸困难及局麻药中毒等并发症。结论 基于CSA计算,L形挡板加压下0.375%罗哌卡因用于SCBPB的ED50为0.239ml/mm2(95%CI:0.215~0.262)。L形挡板加压可显著降低膈肌麻痹的发生率,且无明显副作用。
[关键词] 锁骨上臂丛神经阻滞;罗哌卡因;半数有效量;膈肌麻痹;横截面积
[中图分类号] R614.4" """"[文献标识码] A""" [DOI] 10.3969/j.issn.1673-9701.2025.18.012
ED50 of 0.375% ropivacaine for supraclavicular brachial plexus block with L-shaped pressure baffle intervention based on cross sectional area
ZHANG Liangguang1, ZHANG Long1, PANG Rufa1, QIU Wen1, ZHAO Jinsong1, QI Jianwu2
1.Department of Anesthesiology, Ningbo NO.6 Hospital, Ningbo 315040, Zhejiang, China; 2.Department of Hand Surgery, Ningbo NO.6 Hospital, Ningbo 315040, Zhejiang, China
[Abstract] Objective To explore median effective dose (ED50) of 0.375% ropivacaine based on the cross sectional area (CSA) of supraclavicular brachial plexus block (SCBPB) with L-shaped baffle intervention. Methods Patients scheduled for upper limb surgery from September 2023 to May 2024 at Ningbo NO.6 Hospital were enrolled. Patients were randomly divided into two groups: L-shaped baffle compression group (group L) and non-compression group (group C). CSA of supraclavicular brachial plexus was measured by ultrasound, and 0.375% ropivacaine was administered based on the CSA. The ED50 was determined by using the Dixon up-and-down sequential method, with an initial dose of 0.4 ml/mm² and an incremental difference of 0.04ml/mm². If the block was effective within 30 minutes, the next patient received a lower dose; If ineffective, a higher dose was administered. The process continued until seven cross-over points (ineffective to effective) were observed. ED50 and its 95%CI were calculated by using the Probit method. Adverse reactions, such as phrenic nerve paralysis, nerve injury, dyspnea were recorded. Results The ED50 of 0.375% ropivacaine for SCBPB in group C was 0.254 ml/mm² (95%CI: 0.228-0.278), while in group L, it was 0.239 ml/mm² (95%CI: 0.215-0.262), with no statistically significant difference between two groups (Pgt;0.05). The incidence of phrenic nerve paralysis in group L was significantly lower than that in group C (14.29% vs. 41.67%, Plt;0.05). No significant nerve injuries, dyspnea, or local anesthetic toxicity were observed in either group. Conclusion The ED50 of 0.375% ropivacaine for SCBPB with L-shaped baffle compression, based on the CSA of the brachial plexus, was 0.239 ml/mm² (95%CI: 0.215-0.262). L-shaped baffle compression significantly reduced the incidence of phrenic nerve paralysis without notable side effects.
[Key words] Supraclavicular brachial plexus block; Ropivacaine; Median effective dose; Phrenic nerve paralysis; Cross sectional area
锁骨上臂丛神经阻滞(supraclavicular brachial plexus block,SCBPB)凭借高度集中的神经分布和出色的阻滞效果已广泛应用于上肢手术[1-2];但锁骨上臂丛神经毗邻锁骨下动脉与膈神经,行SCBPB可引发神经毒性或局麻药中毒,增加局麻药剂量还可能提高膈肌麻痹的风险[3-5]。本课题组设计一种L形挡板加压置于超声探头头端,前期研究发现L形挡板加压可有效减少膈肌麻痹的发生,并增强臂丛神经阻滞效果[6]。……
